4//SEC Filing
Camaisa Allan 4
Accession 0001493152-24-001131
CIK 0001855485other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 7:49 PM ET
Size
6.4 KB
Accession
0001493152-24-001131
Insider Transaction Report
Form 4
Camaisa Allan
DirectorCEO, President and Chairman10% Owner
Transactions
- Award
Non-Qualified Stock Options (right to buy)
2023-12-21+100,000→ 100,000 totalExercise: $1.80From: 2023-12-21Exp: 2033-12-23→ Common stock (100,000 underlying)
Footnotes (1)
- [F1]Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on December 21, 2023 (the "Grant Date"), the Reporting Person was granted 100,000 Non-Qualified Stock Options (the "Options") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023 in consideration of Mr. Camaisa personally guaranteeing the raising of $12,500,000 of Series B preferred stock of Calidi Biotherapeutics, a Nevada corporation ("Old Calidi"), in connection with the Agreement and Plan of Merger, as amended ("Merger Agreement"), by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc. ("Merger Sub"), First Light Acquisition Group, LLC, Allan Camaisa and Old Calidi. On September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger. The options were granted in a transaction exempt under Rule 16b-3.
Documents
Issuer
Calidi Biotherapeutics, Inc.
CIK 0001855485
Entity typeother
Related Parties
1- filerCIK 0001990674
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 7:49 PM ET
- Size
- 6.4 KB